Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 7/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3967818 | 0.86 | CRHR1 (0.50) | CRHR1CRHR2KDM4EALDH1A1HPGD | |
| SCHEMBL3968095 | 0.85 | CRHR1 (0.59) | CRHR1CRHR2KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL3964509 | 0.85 | CRHR1 (0.47) | CRHR1CRHR2KDM4EALDH1A1HPGD | |
| SCHEMBL3972191 | 0.85 | CRHR1 (0.47) | CRHR1CRHR2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3962437 | 0.85 | CRHR1 (0.59) | CRHR1CRHR2SMN1; SMN2 | |
| SCHEMBL13763322 | 0.83 | CRHR1 (0.46) | CRHR1CRHR2KDM4EALDH1A1HPGD | |
| SCHEMBL3963656 | 0.83 | CRHR1 (0.46) | CRHR1CRHR2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3965673 | 0.81 | CRHR1 (0.60) | CRHR1CRHR2KDM4ESMN1; SMN2 | |
| SCHEMBL3959431 | 0.80 | CRHR1 (0.48) | CRHR1CRHR2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3964552 | 0.79 | CRHR1 (0.56) | CRHR1CRHR2KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557103-B2 | Imidazopyridazine compounds | ELI LILLY AND COMPANY (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557103-B2 | Imidazopyridazine compounds | ELI LILLY AND COMPANY (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557103-B2 | Imidazopyridazine compounds | ELI LILLY AND COMPANY (US) | 2009-07-07 | — | — | US | disclosed |
| US-20080153828-A1 | Imidazopyridazine Compounds | ELI LILLY AND COMPANY | 2008-06-26 | — | — | US | disclosed |
| US-20080153828-A1 | Imidazopyridazine Compounds | ELI LILLY AND COMPANY | 2008-06-26 | — | — | US | disclosed |
| US-20080153828-A1 | Imidazopyridazine Compounds | ELI LILLY AND COMPANY | 2008-06-26 | — | — | US | disclosed |
| EP-1879896-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006107784-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153828-A1 | Imidazopyridazine Compounds | CRHR1, CRH, CRHR2 | CRHR1 1/4885CRHR2 3/4885KDM4E 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.